(1) Apicella M, Campopiano MC, Mantuano M, et al. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol 2020; 8:782-792.
(2) Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol 2020; 8:813-822.
(3) Zhu L, She ZG, Cheng X, et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab 2020; 31:1068-1077.e3.
(4) Wang S, Ma P, Zhang S, et al. Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study. Diabetologia 2020; 63:2102-2111.
(5) Tittel SR, Rosenbauer J, Kamrath C, et al. Did the COVID-19 Lockdown Affect the Incidence of Pediatric Type 1 Diabetes in Germany? Diabetes Care 2020; 43: e172-e173.
(6) Kamrath C, Mönkemöller K, Biester T, Rohrer TR, Warncke K, Hammersen J, Holl RW. Ketoacidosis in children and adolescents with newly diagnosed type 1 diabetes during the COVID-19 pandemic in Germany. JAMA 2020; 324:801-804.
(7) Jacob L, Rickwood S, Rathmann W, Kostev K. Change in glucose-lowering medication regimens in individuals with type 2 diabetes mellitus during the COVID-19 pandemic in Germany. Diabetes Obes Metab 2020 Dec 15. doi: 10.1111/dom.14293. Epub ahead of print.
(8) Fonseca V, Smith H, Kuhadiya N et al. Impact of a natural disaster on diabetes: exacerbation of disparities and long-term consequences. Diabetes Care 2009; 32: 1632-1638.
(9) Ng J, Atkin SL, Rigby AS, Walton C, Kilpatrick ES. The effect of extensive flooding in Hull on the glycaemic control of patients with diabetes. Diabet Med 2011; 28: 519-524.
(10) Khare J, Jindal S. Observational study on effect of lock down due to COVID 19 on HBA1c levels in patients with diabetes: Experience from Central India. Prim Care Diabetes 2021; 1: S1751-9918(20)30362-4.
(11) Ghosal S, Sinha B, Majumder M, Misra A. Estimation of effects of nationwide lockdown for containing coronavirus infection on worsening of glycosylated haemoglobin and increase in diabetes-related complications: A simulation model using multivariate regression analysis. Diabetes Metab Syndr 2020; 14:319-323.
(12)Joensen LE, Madsen KP, Holm L, Nielsen KA, Rod MH, Petersen AA, Rod NH, Willaing I. Diabetes and COVID-19: psychosocial consequences of the COVID-19 pandemic in people with diabetes in Denmark-what characterizes people with high levels of COVID-19-related worries? Diabet Med 2020; 37:1146-1154.
(13) Kostev K, Kumar S, Konrad M, Bohlken J. Prescription rates of cardiovascular and diabetes therapies prior to and during the COVID-19 lockdown in Germany. Int J Clin Pharmacol Ther 2020; 58:475-481.
(14) Scheidt-Nave C, Barnes B, Beyer AK, Busch MA, Hapke U. Versorgung von chronisch Kranken in Deutschland – Herausforderungen in Zeiten der COVID-19-Pandemie. Journal of Health Monitoring 2020; 5(S10): 2–28.
(15) Mafham MM, Spata E, Goldacre R, et al. COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England. Lancet 2020; 396:381-389.
(16) Marijon E, Karam N, Jost D, et al. Out-of-hospital cardiac arrest during the COVID-19 pandemic in Paris, France: a population-based, observational study. Lancet Public Health 2020; 5:e437-e443.